Rapid pathogen identification and detection molecular diagnosis technology
By using a one-pot process to degrade host nucleic acids with enzyme-coupled magnetic particles and then initiating DNA and RNA with primers, the problem of host signal background interference is solved, enabling rapid and economical creation of DNA and RNA libraries and improving the detection capabilities of high-throughput sequencing.
Patent Information
- Application Number
- CN202380026013.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-09-15
- Filing Date
- 2023-01-07
- Publication Date
- 2024-11-08
Smart Images

Figure CN118922559A_ABST
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to (1) U.S. Provisional Patent Application No. 63 / 297,241, filed on January 7, 2022, and (2) U.S. Provisional Patent Application No. 63 / 406,745, filed on September 15, 2022, the contents of which are incorporated herein by reference in their entireties. Technical Field
[0002] The present disclosure broadly relates to methods for detecting non-host species in host samples, including one-pot DNA / RNA library preparation and techniques for excluding host background to enrich for pathogen DNA and RNA. Background Art
[0003] The ability to detect non-host species residing in or on a host is important for microbial research, for pathogen identification, and for clinical diagnosis of humans, pets, livestock, and wildlife. High-throughput sequencing can be a powerful method for detecting non-host nucleic acids in host fluids, but nucleic acid signals from non-host organisms are often overwhelmed by signals from the host.
[0004] Taking mammalian body fluids (such as plasma, cerebrospinal fluid, nasal secretions, and urine) as a typical example, even if host cells are excluded by low-speed centrifugation, significant amounts of mammalian nucleic acids can still be found in many complexes (including lipoprotein complexes, extracellular vesicles, mitochondria, and apoptotic bodies). For high-throughput sequencing, excluding these host signals is crucial to obtaining a good signal-to-background ratio.
[0005] Many methods have been used in the art to remove this background host signal. Several of these methods involve further use of high-speed centrifugation, followed by selective cell lysis and nucleic acid degradation. However, nucleic acid signals from non-host organisms (including bacteria, protozoa, fungi and DNA / RNA viruses) may be lost during the centrifugation step. Other disadvantages include restrictions on specific types of host cell nucleic acids that can be degraded or inhibited, and insufficient enrichment of non-host organism signals.
[0006] After removing the background host signal, metagenomic sequencing involves the creation of libraries. Typically, DNA libraries and RNA libraries are created using separate samples. It is not always easy to prepare libraries for high-throughput sequencing from biological or medical samples because their nucleic acid content is usually significantly low. In order to cope with this limitation, many traditional methods may require more complex procedures, which are more time-consuming and costly, or are limited to certain nucleic acid samples, or may lose or add some elements that do not belong to the original sample, which means that there is no method for synchronously amplifying nucleic acid samples to avoid or reduce the deviation between different types of nucleic acids of the same target, especially when the nucleic acid sample amount is only at the picogram level. Therefore, it may be difficult to create DNA and RNA libraries separately, increase processing costs and increase sample processing time.
[0007] U.S. Patent No. 5,731,171 (Bohlander et al.) provides a sequence-independent amplification (SIA) based on PCR that can amplify DNA from trace amounts (such as from microdissected chromosome material). The method includes an initial primer, which is composed of 4-8 random nucleotides at the 3' end and 10-30 nucleotides of a defined (non-random) sequence at the 5' end, wherein the random nucleotides can be any of G / A / T / C (in any order). The 3' end of the initial primer should be complementary to a random site in the entire target DNA fragment, and the defined sequence should constitute a PCR primer that does not form self-homology, has no consecutive identical nucleotides, and is not excessively rich in G:C or A:T.
[0008] U.S. Patent No. 6,124,120 (Lizardi et al.) provides a non-PCR-based method of multiple strand displacement amplification (MDA) that uses two sets of primers complementary to a pair of double-stranded DNA, wherein some of the intermediate primers are displaced by a polymerase during replication. Another embodiment of the patent also uses a set of random primers to sequence the entire genome. A highly processive polymerase is used during the replication process to synthesize overlapping copies of the entire genome in a short period of time.
[0009] However, neither Bohlander et al. nor Lizardi et al. can be used to simultaneously amplify samples containing a mixture of different nucleic acids (including deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or any analogs thereof) without bias, wherein the nucleic acids are single-stranded or double-stranded, or both.
[0010] U.S. Pat. No. 7,402,386 (Kurn et al.) discloses a method for global amplification of DNA / RNA polynucleotide targets using RNA-DNA composite primers and DNA-dependent and RNA-dependent DNA polymerases. The method involves cleaving the RNA portion from the RNA / DNA heteroduplex prior to subsequent amplification.
[0011] U.S. Patent No. 7,718,403 and U.S. Patent No. 8,206,913 (Kamberov etc.) disclose the method for whole genome amplification (WGA) and whole transcriptome amplification (WTA), the method described includes library generation step and library amplification step, relates to using random primers and specific DNA polymerase to generate the first chain from DNA / RNA template in the library generation step, wherein the variable region of primer comprises up to 3 random nucleotides, each comprises two non-complementary nucleotides, so that primers will not self-hybridize or cross-hybridize with each other.If there are only up to 3 random nucleotides in each random primer, then selecting random nucleotides comprising two non-complementary nucleotide bases instead of random nucleotides comprising at least three non-complementary nucleotide bases can not effectively reduce the cross-hybridization in the random primer pool, because PCR prefers to generate short amplicon.In order to prevent polymerase from chelating to non-productive amplicon, it is important to reduce the ability to form non-specific amplicon.
[0012] U.S. Pat. No. 8,741,606 (Casbon et al.) discloses a method for labeling a degenerate base region (DBR) to both ends of a nucleic acid molecule to be sequenced, thereby generating an asymmetrically labeled nucleic acid molecule due to two different DBRs. The DBRs include sequencing primer sites for subsequent PCR. In certain embodiments of '606, the DBRs may be 3 to 10 random nucleotides long, and each DBR may have a different base composition, for example, a 4-base DBR may have any of the following compositions: NNNN; NRSN; SWSW; BDHV (according to the IUPAC nucleotide code). '606 involves adding two different DBRs to both ends of a nucleic acid molecule to be sequenced, as well as some functional domains, such as a unique multiple identifier and sequencing primer sites for sequencing purposes, but it was not originally designed for preparing libraries from a mixture of different nucleic acids including both DNA and RNA in single-stranded or double-stranded form.
[0013] U.S. Pat. No. 8,728,766 (Casbon et al.) discloses a method for processing a genomic DNA sample, the method comprising hybridizing a genomic sample of an initial target DNA molecule using a group of first primers, wherein the first primers include different DBR sequences at 5' of a target-specific sequence, and the different DBR sequences include at least one of R, Y, S, W, K, M, B, D, H, V, N, or modified versions thereof according to the IUPAC nucleotide code. In certain examples, RYB serves as the DBR sequence, and DHVB serves as the target-specific sequence. In these examples, the total number of different sequences from these random nucleotides can be 972 (2×2×3×3×3×3). There are still only three random nucleotides in the DBR sequence used in the first primer of '766. Under appropriate conditions, cross-hybridization between primers may still occur.
[0014] U.S. Pat. No. 9,920,355 (Osborne et al.) provides a library preparation method that includes adding different concentrations of deoxymethylcytidine triphosphate to the RT reaction mix for first-strand, second-strand generation and / or PCR amplification to promote fragmentation using specific restriction enzyme digestion.
[0015] In view of the above, it is necessary to solve or at least improve one or more of the above problems. In particular, it is necessary to provide methods for degrading undesirable nucleic acids in samples, and it is necessary to quickly create DNA and RNA libraries in a cost-effective manner to accurately and quickly detect non-host species and related components in host samples. Such technology enables the widespread use of next-generation metagenomic sequencing, especially for human pathogen detection. Summary of the invention
[0016] In one aspect, the present invention provides an improved body fluid sample metagenomic sequencing process. In a part of the process, by contacting the sample with magnetic particles coupled to an enzyme (such as a nuclease), undesirable nucleic acids in the sample are degraded, and the enzyme is used to degrade undesirable nucleic acids in the sample. The magnetic particles are coupled to the enzyme and are capable of degrading both DNA and RNA, and then a magnetic field is applied to remove the magnetic particles coupled to the enzyme from the sample. DNA and RNA libraries are created from degraded samples by a one-pot process.
[0017] In another aspect, a one-pot process utilizes one set of primers to prime single-stranded DNA and simultaneously prime RNA.
[0018] In another aspect, the sample comprises more than one type of nucleic acid as a template for subsequent extension and amplification, the nucleic acid comprising single-stranded and / or double-stranded DNA and / or RNA, and the one-pot process comprises preparing a first DNA strand from the sample, the preparing the first DNA strand comprising annealing one or more first DNA strand generating primers to any one of the DNA and / or RNA templates, and extending from the annealed first DNA strand generating primers, the extending comprising using a DNA polymerase capable of synthesizing a first DNA strand from one or both of the DNA and / or RNA templates to obtain a first DNA strand.
[0019] In another aspect, the enzyme-coupled magnetic particles include magnetic particles coupled to both DNAse and RNAse, magnetic particles coupled to enzymes capable of degrading both DNA and RNA, a mixture comprising magnetic particles coupled to DNAse and magnetic particles coupled to RNAse, or a combination thereof.
[0020] In another aspect, the undesired nucleic acid comprises cell-free nucleic acid.
[0021] In another aspect, degrading unwanted nucleic acids in the sample further comprises applying a lysing agent to the sample for selectively lysing biological complexes in the sample to release the unwanted nucleic acids for enzymatic degradation, optionally wherein the lysing agent is substantially incapable of lysing intact cells and viruses selected from bacteria, protozoa, fungi and parasites.
[0022] In another aspect, the lysing agent comprises a mild detergent.
[0023] In another aspect, the sample is a sample derived from a host subject and the undesired nucleic acids are host nucleic acids, but are substantially free of non-host nucleic acids.
[0024] In another aspect, the invention provides a method for detecting non-host species in a host sample. The host sample is contacted with a magnetic particle coupled to an enzyme to degrade the cell-free host nucleic acid present in the host sample, wherein the magnetic particle coupled to the enzyme can degrade both DNA and RNA. A magnetic field is applied to remove the magnetic particle coupled to the enzyme from the host sample. A DNA and RNA library is created from the degraded sample with a one-pot process, and then the presence of non-host nucleic acids is detected from the DNA and RNA library.
[0025] In another aspect, a one-pot process uses one set of primers to prime single-stranded DNA and simultaneously prime RNA.
[0026] In another aspect, the sample comprises more than one type of nucleic acid as a template for subsequent extension and amplification, the nucleic acid comprising single-stranded and / or double-stranded DNA and / or RNA, and the one-pot process comprises preparing a first DNA chain from the sample, the preparing the first DNA chain comprising annealing one or more first DNA chain generating primers to any one of the DNA and / or RNA templates, and extending from the annealed first DNA chain generating primers, the extending comprising using a DNA polymerase capable of synthesizing a first DNA chain from one or both of the DNA and / or RNA templates to obtain a first DNA chain.
[0027] In another aspect, host cells are removed from the host sample prior to contacting the host sample with the magnetic particles coupled to the enzyme.
[0028] In another aspect, prior to the contacting step, a first lysing agent is applied to the host sample for selectively lysing the biological complex to release the host nucleic acid contained therein, optionally wherein the first lysing agent is substantially incapable of lysing non-host species to release the nucleic acid contained therein for enzymatic degradation. The lysing agent comprises a mild detergent.
[0029] The step of detecting the presence of non-host nucleic acid in the sample comprises applying a second lysing agent to the host sample for lysing the non-host species to release the nucleic acid contained therein.
[0030] In another aspect, the second lysing agent comprises lysing particles capable of imparting a mechanical force to lyse the non-host species and release the nucleic acids contained therein.
[0031] In another aspect, detecting the presence of a non-host nucleic acid in a sample comprises sequencing the non-host nucleic acid. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 is a schematic flow chart illustrating various process steps according to an exemplary embodiment of the method disclosed herein.
[0033] Figure 2 is an amplification graph showing amplification curves of PCR products using primers specific to each non-host organism or a representative human gene according to exemplary embodiments disclosed herein.
[0034] Figure 3 The embodiment of the method is schematically illustrated, using the first strand generating primer, the second strand generating primer and the corresponding amplification primer of the present invention to generate double-stranded DNA molecules from different nucleic acids.
[0035] Figure 4 The embodiment of the method is schematically described. Figure 3The double-stranded DNA molecules obtained by amplification of the second DNA strand shown are modified and fragmented to generate double-stranded DNA molecules with a linear length shorter than 1000 nucleotides.
[0036] Figure 5 The embodiment of the method is schematically illustrated. Figure 4 The fragmented double-stranded DNA molecules shown have corresponding adapter sequences appended for barcoding.
[0037] Figure 6 Schematically illustrating an embodiment of the invention, a library is prepared from a sample with RNA template according to the methods and components described herein.
[0038] Figure 7A-7D According to Example 3, it is described that by using a method for targeting human 18S ( Fig. 7A )、U2AF1( Figure 7B )、GAPDH coding region ( Figure 7C ) and GAPDH 3'UTR( Fig.7D ) from 5 ng / 500 pg HEK293 cell RNA (dT 5 ng / 500 pg) normalized to input RNA and a cleaned library preparation prepared using 5 ng / 500 pg dT-adapter B6 sequence (dT:B6 5g / 500 pg).
[0039] Figure 8 Two graphs illustrating transcript reads between samples using 5 ng of dT-adapter B6 sequence (dT:B6 5ng) and 5ng of dT, and between dT:B6 5ng and dT:B6 500pg. definition
[0040] The term "nucleic acid" as used herein broadly includes ribonucleic acid (RNA), deoxyribonucleic acid (DNA) or parts / fragments thereof. The term also includes various forms of nucleic acid, including intracellular nucleic acid, extracellular nucleic acid, acellular nucleic acid, unencapsulated nucleic acid, encapsulated nucleic acid, protected nucleic acid, unprotected nucleic acid, cell-free nucleic acid, nucleic acid of human / animal / mammal, microbial nucleic acid (such as bacteria, fungi, viruses), host cell nucleic acid and non-host cell nucleic acid.
[0041] As used herein, the term "unwanted nucleic acids" refers to nucleic acids that are not desired to be present as intact nucleic acids for a particular step, but this does not necessarily mean that these nucleic acids have no use or purpose at all (e.g., for other steps or methods). For example, if a particular step requires that the sample be free of cell-free host nucleic acids, then these cell-free host nucleic acids can be considered undesirable for that particular step, even though these nucleic acids may be useful for other steps. Thus, cell-free host nucleic acids can be considered undesirable for a particular step and therefore removed / degraded from the sample before or at a particular step; and when they become desirable or no longer undesirable in other steps, they can be reintroduced into the sample, for example, by lysing intact host cells.
[0042] The term "magnetism" as used herein refers to the magnetism of a material. The term "magnetic particles" as used herein refers to particles made of a material having magnetism. Magnetic particles are able to interact with a magnetic field to generate an attractive or repulsive force. If a magnetic field is applied to the magnetic particles, the particles will be magnetized. Magnetized particles can be divided into ferromagnetism and paramagnetism, depending on the type of magnetization produced by the applied magnetic field. Ferromagnetic materials are substances that are strongly magnetized in the same direction as the magnetic field when a strong magnetic field is applied externally, and remain magnetized even after the external magnetic field is removed. The average diameter of the magnetic particles may be in the range of nanometers, micrometers or millimeters. The magnetic particles may include magnetic beads / microbeads and / or nanoparticles.
[0043] As used herein, the term "micro" should be broadly interpreted to include sizes from about 1 micron to about 1000 microns.
[0044] As used herein, the term "nano" should be interpreted broadly to include dimensions less than about 1000 nm.
[0045] The term "particle" as used herein refers generally to a discrete entity or discrete body. The particles described herein may include organic particles, inorganic particles, or biological particles. The particles described herein may also be large particles formed by fragments of small objects or agglomerates of multiple sub-particles. The particles of the present disclosure may be spherical, substantially spherical, or non-spherical, such as irregularly shaped particles or ellipsoidal particles. When used to refer to particles, the term "size" refers generally to the maximum dimension of the particle. For example, when the particle is substantially spherical, the term "size" may refer to the diameter of the particle; or when the particle is substantially non-spherical, the term "size" may refer to the maximum length of the particle.
[0046] The "one-pot method" described herein may refer to a single step using a set of primers that simultaneously prime single-stranded DNA and RNA (such as mRNA) (e.g., by having a primer with an oligo-dT sequence at the 5' end of two random nucleotides), under appropriate reverse transcription conditions with a polymerase capable of both DNA extension and RNA transcription, enabling the generation of cDNA chains from both DNA and RNA templates, or any other oligonucleotide synthesis method that does not require additional purification or other methods for separating one type of nucleic acid from other nucleic acids (which is due to the limitations of oligonucleotide synthesis protocols provided by traditional techniques).
[0047] Unless otherwise stated, the terms "coupled" or "connected" as used in this description are intended to encompass both being directly connected or being connected through one or more intermediate means.
[0048] As used herein, the term "associated with" when referring to two elements refers to a broad relationship between the two elements. Such a relationship includes, but is not limited to, a physical, chemical, or biological relationship. For example, when element A is associated with element B, elements A and B may be directly or indirectly connected, or element A may contain element B, or vice versa.
[0049] When referring to two elements, the term “adjacent” as used herein means that one element is adjacent to the other element, and may be, but is not limited to, the two elements contacting each other, or may also include that the elements are separated by one or more other elements disposed therebetween.
[0050] As used herein, the term "and / or", for example "X and / or Y", is understood to mean "X and Y" or "X or Y", and should be construed to provide explicit support for both meanings or either meaning.
[0051] In addition, in the description herein, whenever the word "substantially" is used, it should be understood to include, but not limited to, "entirely" or "completely", etc. In addition, whenever terms such as "include" and "comprises" are used, they are intended to be non-limiting descriptive language, in that they broadly include the elements / components listed after such terms, as well as other components not explicitly listed. For example, when "include / comprises" is used, mentioning "a" feature is also intended to mention "at least one" of the feature. Terms such as "consisting of..." and "composed of..." can be considered as subsets of terms such as "including" and "comprising" in appropriate contexts. Therefore, in the embodiments disclosed herein using terms such as "including" and "comprising", it can be understood that these embodiments provide teachings of corresponding embodiments using terms such as "consisting of..." and "composed of..." In addition, whenever terms such as "about" and "approximately" are used, reasonable variations are generally intended, such as a variation of + / - 5% of the disclosed value, or a variation of 4% of the disclosed value, or a variation of 3% of the disclosed value, or a variation of 2% of the disclosed value, or a variation of 1% of the disclosed value.
[0052] In addition, in the description herein, certain values may be disclosed in the form of ranges. The values showing the endpoints of the ranges are intended to illustrate preferred ranges. Whenever a range is described, it is intended that the range covers and teaches all possible subranges and individual values within the range. In other words, the endpoints of the range should not be understood as unchanging restrictions. For example, the description of a range of 1% to 5% is intended to have specifically disclosed subranges 1% to 2%, 1% to 3%, 1% to 4%, 2% to 3%, etc., and individual values within the range, such as 1%, 2%, 3%, 4% and 5%. The above-mentioned specifically disclosed intentions are applicable to any depth / breadth of the range.
[0053] In addition, when describing certain embodiments, the present disclosure may have disclosed the method and / or process as a specific ordering of steps. However, unless otherwise required, it should be understood that the method or process should not be limited to the specific ordering of the steps disclosed. Other orderings of steps are also possible. The specific order of the steps disclosed herein should not be understood as an excessive restriction. Unless otherwise required, the method and / or process disclosed herein should not be limited to performing the steps in the order written. The ordering of the steps can be changed and still be within the scope of the present disclosure.
[0054] In addition, it will be understood that although the present disclosure provides embodiments having one or more of the features / characteristics discussed herein, one or more of these features / characteristics may also be abandoned in other alternative embodiments, and the present disclosure provides support for these abandonment statements and these related alternative embodiments. DETAILED DESCRIPTION
[0055] The present invention provides methods for degrading unwanted nucleic acids in samples, and for rapidly creating DNA and RNA libraries in a cost-effective manner, so that non-host species in host samples can be accurately and rapidly detected. This technology enables the widespread application of next-generation metagenomic sequencing, especially for human pathogen detection.
[0056] The first part of this specification focuses on degrading undesirable nucleic acids in a sample by contacting the sample with magnetic particles coupled to an enzyme to degrade undesirable nucleic acids in the sample. The magnetic particles coupled to the enzyme can degrade both DNA and RNA. A magnetic field is applied to remove the magnetic particles coupled to the enzyme from the sample.
[0057] The second part of this note focuses on the one-pot synthesis of DNA / RNA libraries from degraded samples. These two techniques can be used together, for example, in metagenomic sequencing, enabling the detection of pathogens in a non-targeted manner. That is, the examination of pathogens without a priori guessing what pathogens may be present in the sample. Together, these techniques enable rapid and economical metagenomic sequencing.
[0058] Degrades unwanted nucleic acids in samples.
[0059] Disclosed below are exemplary, non-limiting embodiments of methods for degrading unwanted nucleic acids in a sample, methods for detecting non-host species in a host sample, and related compositions and methods.
[0060] Provided is a method for degrading undesirable nucleic acids in a sample. In various embodiments, the method comprises contacting / incubating the sample with a magnetic particle coupled to an enzyme to degrade undesirable nucleic acids present in the sample, wherein the magnetic particle coupled to the enzyme is capable of degrading DNA, RNA, or both DNA and RNA. Advantageously, in various embodiments, the undesirable nucleic acids include free / unprotected nucleic acids that can be selectively degraded by an enzyme, thereby excluding free / unprotected nucleic acids in the sample.
[0061] In various embodiments, the undesirable nucleic acids are degraded or digested in a manner or to an extent such that the signals of the undesirable nucleic acids are substantially removed or reduced when the sample is subsequently processed for nucleic acid detection. For example, after the undesirable nucleic acids are substantially degraded or digested, they do not substantially interfere negatively with the detection of the presence or identity of other nucleic acids of interest, e.g., a good signal-to-background ratio for the nucleic acids of interest can be obtained, e.g., in a high-throughput sequencing process.
[0062] In various embodiments, the method can remove at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or at least about 100% of the undesirable nucleic acids. In various embodiments, the method can reduce the signal from the undesirable nucleic acids by at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or at least about 100%.
[0063] In various embodiments, the method is capable of enriching the nucleic acid of interest by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, or at least about 10-fold. In various embodiments, the method is capable of increasing the signal of the nucleic acid of interest by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, or at least about 10-fold.
[0064] In various embodiments, undesirable nucleic acids include DNA, RNA or a combination thereof. DNA and RNA can be single-stranded or double-stranded. These DNA and RNA can be the original full-length DNA or RNA that resides in the organism / cell from which they are derived, or can be shortened portions / fragments of the original DNA or RNA.
[0065] In various embodiments, undesirable nucleic acid is derived from / derived from / released from the same species. In different embodiments, undesirable nucleic acid is composed of a nucleic acid derived from / derived from / released from a species. For example, when the nucleic acid of interest includes a nucleic acid derived from / derived from / released from a non-host species, undesirable nucleic acid may include a nucleic acid derived from / derived from / released from a host species. Examples of host and non-host species include, but are not limited to, animals, plants, microorganisms, protozoa, fungi, bacteria, viruses and parasites. Bacteria include gram-negative bacteria and gram-positive bacteria. Examples of gram-negative bacteria include, but are not limited to, Escherichia coli, Pseudomonas, Salmonella, Moraxella, Helicobacter, Stenotrophomonas, Bdellovibrio, Legionella and Neisseria. Examples of gram-positive bacteria include, but are not limited to, Streptococci, Staphylococci, Enterococci, Bacillus, Corynebacterium, Listeria, Lactobacilli, Erysipelothrix, and Clostridium. Viruses include DNA viruses and RNA viruses. Examples of DNA viruses include, but are not limited to, viruses from the Adenoviridae (e.g., canine hepatitis virus, common cold virus), the Herpesviridae (e.g., herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus), and the Poxviridae (e.g., smallpox virus, vaccinia virus, myxoma virus, monkeypox, vaccinia virus). Examples of RNA viruses include, but are not limited to, those from the Retroviridae (e.g., human immunodeficiency virus), Flaviviridae (e.g., dengue virus, hepatitis C virus), Orthomyxoviridae (influenza), and Coronaviridae (e.g., human coronavirus, SARS coronavirus, SARS-CoV-2). Fungi include those from the Chytridiomycota (chytrid fungi), Zygomycota (bread mold), Ascomycota (yeast and capsule fungi) (e.g., Saccharomyces), and Basidiomycota (rod-shaped fungi) (e.g., Cryptococcus).In various embodiments, undesirable nucleic acids include nucleic acids derived from / derived from / released from host cells, eukaryotic cells, animal cells, mammalian cells and / or human cells. In various embodiments, undesirable nucleic acids include host nucleic acids. In various embodiments, undesirable nucleic acids include human nucleic acids. In various embodiments, undesirable nucleic acids include mitochondrial and / or ribosomal RNA. Non-limiting examples of undesirable nucleic acids include actin β (ACTB), 3-phosphoglyceraldehyde dehydrogenase (GADPH), mitochondrial encoded 12S RRNA (MT-RNR1), mitochondrial encoded 16S RRNA (MT-RNR2), ribosomal protein S18 gene (RPS18) and combinations thereof. In some embodiments, undesirable nucleic acids do not include nucleic acids derived from / derived from / released from non-eukaryotic cells, prokaryotic cells, non-animal cells, non-mammalian cells, non-human cells and / or viruses. In various embodiments, undesirable nucleic acids do not include or are substantially free of non-host cell nucleic acids (e.g., bacteria, fungi, protozoa, viruses, parasite nucleic acids).
[0066] Unwanted nucleic acids can be protected (e.g., membrane-bound nucleic acids, such as those encapsulated by or contained in vesicles, exosomes, etc.) or unprotected (e.g., nucleic acids in free form, cell-free nucleic acids, extracellular nucleic acids, etc.). Unwanted nucleic acids can be found or circulate in biological fluids of a host subject (e.g., plasma, cerebrospinal fluid, nasal secretions, urine, mucus, etc.). These undesired nucleic acids may be released into a biological fluid or sample due to accidental lysis of cells, or due to naturally occurring processes (e.g., cell death, apoptosis, or the production of vesicles, exosomes, etc. for intercellular communication). Unwanted nucleic acids can be isolated or present as part of a biological complex.
[0067] Biocomplexes can include any product (e.g., extracellular product) produced by or derived from a cell, such as a eukaryotic cell and / or a complete cell. Therefore, in various embodiments, biocomplexes do not include cells (e.g., eukaryotic cells and / or complete cells) and viruses. Biocomplexes also include, for example, cellular components released from their source cells due to apoptosis / death / lysis / accidental lysis of cells. Examples of biocomplexes include, but are not limited to, membrane-bound particles / molecules (e.g., extracellular membrane-bound particles / molecules), lipoproteins, extracellular vesicles, microvesicles, exosomes, organelles (e.g., mitochondria), apoptotic bodies, etc. In various embodiments, membrane-bound particles / molecules include single membrane-bound particles / molecules. In various embodiments, membrane-bound particles / molecules include particles / molecules enclosed by lipid bilayers.
[0068] In various embodiments, enzyme includes nuclease such as phosphodiesterase, DNAse, RNAse or its combination. In various embodiments, nuclease can degrade DNA, RNA or both DNA and RNA. In some embodiments, the nuclease is a nuclease that can serve as both DNAse and RNAse simultaneously, i.e., a nuclease that can digest / degrade DNA and RNA. Nuclease can be an endonuclease, an exonuclease, or can have the activity of both endonuclease and exonuclease. Nuclease can be a recombinant nuclease, a synthetic nuclease or a wild-type nuclease or a naturally occurring nuclease, such as a nuclease purified from a living organism (e.g., an animal). Examples of nucleases include, but are not limited to, RNAse A, RNAse T1, RNase I, baseline-zero DNase, benzonase, DNase I, DNase II, endonuclease III, endonuclease IV, endonuclease V, endonuclease VIII, exonuclease I, exonuclease III, exonuclease V, exonuclease VII, exonuclease VIII, exonuclease T, lambda exonuclease, micrococcal nuclease, mung bean nuclease, nuclease BAL-31, nuclease P1, nuclease SI, T4 endonuclease V, T5 exonuclease, T7 endonuclease I, T7 exonuclease. In various embodiments, the nuclease is selected from the group consisting of metazoan DNAase I, RNAse A, RNAse T1, Benzonase, and combinations thereof.
[0069] In various embodiments, the nuclease is capable of degrading single-stranded nucleic acids (eg, single-stranded specific nucleases), double-stranded nucleic acids (eg, double-stranded specific nucleases), or both single-stranded and double-stranded nucleic acids.
[0070] In various embodiments, the nuclease is coupled to the magnetic particles. Nucleases can be coupled or conjugated to magnetic particles using a variety of different techniques. For example, magnetic particles can be treated to provide a surface coating of a polymer carrying a functional group, and the nuclease can be conjugated to the functionalized magnetic particles by covalent connections such as click chemistry, epoxyamine adducts, amide bonds, ester bonds, disulfide bonds, etc. Any suitable reactive group present on the surface of the nuclease and / or magnetic particles (e.g., functionalized magnetic particles) can be used to covalently bind the enzyme to the surface of the magnetic particles. The functional group may include, but is not limited to, a phosphate group, a phosphonic acid group, a sulfate group, a sulfonic acid group, an azide group, an alkyne group, an olefin group, an anhydride group, an aldehyde group, an amine group, a hydroxyl group, a carboxyl group, a tetrazine group, a thiol group, and an epoxy group. It is understood that other suitable methods for conjugating nucleases to magnetic particles can also be used, as long as these methods can fully fix the nuclease on the magnetic particles without eliminating the effectiveness of the nuclease degrading nucleic acids, nor eliminating the effectiveness of manipulating the magnetic particles by applying a magnetic field.
[0071] In some embodiments, multiple nucleases can be coupled to a single magnetic particle. The multiple nucleases coupled to the magnetic particle can be nucleases of the same type or nucleases belonging to the same category (e.g., DNAse, RNAse or phosphodiesterase, e.g., single-stranded specific nuclease or double-stranded specific nuclease). Or, the multiple nucleases coupled to the magnetic particle can be different or from different categories of nucleases. For example, DNAse and RNAse can be both coupled to a single magnetic particle. If the ability of both DNAse and RNAse is needed simultaneously, this is advantageous. For example, single-stranded specific nuclease and double-stranded specific nuclease can be both coupled to a single magnetic particle. If both single-stranded and double-stranded DNA / RNA are needed to be degraded simultaneously, this is advantageous. In some embodiments, a single nuclease or a single type of nuclease can be coupled to a single magnetic particle. Even if the ability of both DNAse and RNAse is needed at the same time, or both single-stranded and double-stranded DNA / RNA need to be removed at the same time, this is also possible, because the single nuclease or single type of nuclease can be a nuclease (such as Benzonase and phosphodiesterase) that can serve as DNAse and RNAse at the same time, or a nuclease (such as DNAse I) that can degrade both single-stranded and double-stranded DNA / RNA at the same time. In addition, since various embodiments utilize multiple magnetic particles, each magnetic particle can be coupled to a nuclease with an enzymatic activity different from other magnetic particles, and therefore the activity of both DNAse and RNAse can be provided overall. In various embodiments, the magnetic particles coupled with nucleases include magnetic particles coupled with DNAse and RNAse, magnetic particles coupled with nucleases that can degrade both DNA and RNA, a mixture of magnetic particles coupled with DNAse and magnetic particles coupled with RNAse, or a combination thereof. Depending on the nature and / or identity of the unwanted nucleic acid (e.g., whether it is DNA and / or RNA, single-stranded and / or double-stranded), one or more different nucleases can be appropriately selected and coupled to the magnetic particles to appropriately remove the unwanted nucleic acid.
[0072] In various embodiments, the method includes applying a magnetic field to remove magnetic particles coupled to the nuclease from the sample. Advantageously, embodiments of the method can effectively remove traces of nuclease activity by effectively removing the magnetic particles coupled to the nuclease using non-contact means such as a magnetic field. This can prevent the nuclease from proceeding to the next reaction or step. Therefore, various embodiments of the methods disclosed herein provide effective methods for degrading / digesting undesirable nucleic acids in a sample with a nuclease and subsequently removing nuclease activity by creatively employing magnetic particles coupled to the nuclease and a magnetic field.
[0073] The magnetic field can be a magnetic field that exerts a magnetic force on the magnetic particles so that they are concentrated, assembled, gathered or merged together. The magnetic force can be an attractive force or a repulsive force. In various embodiments, the magnetic force is an attractive force that attracts and concentrates the magnetic particles. In various embodiments, the sample is then removed from the magnetic particles by removing the solution / buffer solution / supernatant (e.g., by pouring or pipetting) from the magnetic particles, and the magnetic particles are kept attracted and concentrated by the magnetic field at a specific part of the storage container / container (e.g., a test tube) holding the sample. Alternatively, the magnetic particles can be directly removed from the sample by using the attractive force given by the magnetic field to move the magnetic particles out of the sample. In various embodiments, since the nuclease is coupled to the magnetic particles, removing the magnetic particles from the sample or vice versa will make the sample / solution / buffer solution / supernatant substantially free of added nuclease.
[0074] In various embodiments, the magnetic field is applied by using a magnet. The magnet may be a permanent magnet or an electromagnet. For example, the magnet may be a permanent magnet, or the magnet may be an electromagnet comprising a coil embedded in a base member and connected to an external power source. Combinations of different magnet types may also be used. In the case where the magnet is a permanent magnet, the system may be able to perform measurements without an external power source. In various embodiments, the magnet used is in the form of a magnetic stand.
[0075] Undesirable nucleic acids can be used as part of a biocomplex. For example, undesirable nucleic acids can be contained in membrane-bound particles / molecules, optionally single membrane-bound particles / molecules (e.g., extracellular membrane-bound particles / molecules), lipoproteins, extracellular vesicles, microvesicles, exosomes, organelles (e.g., mitochondria), apoptotic bodies, etc. For example, undesirable nucleic acids can be wrapped / encapsulated in a lipid bilayer, optionally in a single lipid bilayer. Therefore, in various embodiments, the method further includes applying a lysing agent to the sample for selectively cleaving the biocomplex containing the undesirable nucleic acid in the sample, thereby releasing the undesirable nucleic acid for nuclease degradation. This step allows undesirable nucleic acids residing in the biocomplex to be released into the sample for nuclease degradation. Advantageously, this can allow for cleaner and more comprehensive removal of undesirable nucleic acids, which may also increase background noise when detecting other nucleic acids of interest.
[0076] In some embodiments, it may not be necessary to apply a lysing agent, particularly if the method is deployed in a separate use case where selective lysis is not required. For example, selective enrichment of specific types of cells or biological complexes (such as exosomes) from complex biological fluids (such as blood) may cause accidental lysis of cells, thereby releasing nucleic acids into solution. Therefore, nuclease-coupled magnetic particles / beads can be applied to bulk mixtures to degrade "environmental" nucleic acids without washing the cells, and the particles / beads can then be easily removed with a magnet without the need for a washing step. Advantageously, this allows for the efficient removal of "environmental" nucleic acids, which otherwise may be captured along with the signal nucleic acids in subsequent purification steps and adversely affect the accurate measurement of specific nucleic acid signals.
[0077] In various embodiments, the lysing agent is substantially incapable of lysing cells / viruses protected by cell walls (e.g., bacteria and fungi), double membranes (e.g., parasites), and / or protein coats (e.g., protozoa and viruses protected by pellicles) to release nucleic acids contained therein for degradation by magnetic particles coupled to nucleases. In various embodiments, the lysing agent is substantially incapable of lysing viruses and / or intact cells (e.g., intact cells selected from bacteria, protozoa, fungi, parasites, and combinations thereof) to release nucleic acids contained therein for degradation by magnetic particles coupled to nucleases. In various embodiments, intact cells and / or viruses contain nucleic acids of interest. Therefore, in various embodiments, intact cells and / or viruses are not actively lysed by the lysing agent, thereby preventing the nucleic acids of interest from leaking into the sample and preventing them from being subsequently undesirably degraded by nucleases even before detecting and identifying these nucleic acids of interest. In some embodiments, intact cells may not contain nucleic acids of interest, but even so will not substantially contribute to background noise during detection and identification of nucleic acids of interest; therefore, it may not be necessary to release and degrade the nucleic acids contained in these intact cells. Thus, in various embodiments, the lysing agent is a selective lysing agent that selectively lyses only free biological complexes that contain undesirable nucleic acids and that may contribute background noise during detection and identification of other nucleic acids of interest. Advantageously, when the nucleic acids of interest are contained in non-host species / organisms such as bacteria, fungi, protozoa, parasites, and viruses, the method may be able to keep intact bacterial / fungal nucleic acids protected by cell walls, parasite nucleic acids protected by double membranes, and virus / protozoa protected by proteins.
[0078] In various embodiments, the lysing agent comprises a mild detergent. A mild detergent may be one that is capable of lysing free biological complexes but not intact cells or viruses.
[0079] In various embodiments, before the step of contacting / hatching the sample with the magnetic particles coupled with nuclease, the sample may be substantially free of or free of intact cells containing undesirable nucleic acids. For example, if the nucleic acid of the host cell is not of interest, and may contribute background noise when detecting or differentiating the nucleic acid of interest (such as nucleic acid from non-host cells), then before the step of contacting / hatching the sample with the magnetic particles coupled with nuclease, the sample may be substantially free of or free of intact host cells. Therefore, in various embodiments, the method further includes the step of removing intact cells containing undesirable nucleic acids before the contacting / hatching step. In some embodiments, the step of removing intact cells containing undesirable nucleic acids can be carried out after the contacting / hatching step. The suitable method of removing intact cells containing undesirable nucleic acids from the sample includes centrifugation (for example, low-speed centrifugation), filtration, decantation or similar methods and combinations thereof.
[0080] In various embodiments, the sample comprises a biological sample. In various embodiments, the biological sample comprises a fluid biological sample or a liquid biological sample. Fluid biological sample or liquid biological sample can be blood, serum, blood plasma, sputum, lavage fluid, cerebrospinal fluid, urine, semen, sweat, tears, saliva, etc. In some embodiments, fluid biological sample or liquid biological sample comprises whole blood, serum, blood plasma or its processed fraction. In some embodiments, the fluid biological sample comprises serum or blood plasma. In various embodiments, the sample comprises a sample derived from a host subject, and the undesirable nucleic acid comprises host nucleic acid, but does not substantially or does not comprise non-host nucleic acid. In various embodiments, the sample comprises non-host species, cell organisms or viruses. Advantageously, the method can be used to detect non-host species residing in or on a host.
[0081] Therefore, a method for detecting non-host species in a host sample is also provided, the method comprising contacting / incubating the host sample with magnetic particles coupled to a nuclease to degrade cell-free host nucleic acids present in the host sample, wherein the magnetic particles coupled to the nuclease are capable of degrading DNA, RNA, or both DNA and RNA; applying a magnetic field to remove the magnetic particles coupled to the nuclease from the host sample; and detecting the presence of non-host nucleic acids in the sample. The contact / incubation step can be performed under similar conditions to those previously described (e.g., temperature and duration). The method may further include removing host cells from the host sample before contacting / incubating the host sample with the magnetic particles coupled to the nuclease.
[0082] In various embodiments, the method of detecting non-host species in a host sample further includes applying a first lysing agent to the host sample prior to contacting / incubating the host sample with the magnetic particles coupled to the nuclease for selectively lysing the cell-free host biological complex. The first lysing agent may be substantially incapable of lysing the non-host species to release the nucleic acids contained therein for degradation by the magnetic particles coupled to the nuclease. The first lysing agent may include a mild detergent having similar properties (e.g., identity, properties, and concentration) as previously described.
[0083] In various embodiments, the method for detecting non-host species in a host sample further includes applying a second cleavage agent to the host sample for cracking non-host species to release nucleic acids contained therein. In various embodiments, the second cleavage agent is different from the first cleavage agent. The second cleavage agent can utilize a mechanism of action similar or different from the first cleavage agent to crack non-host species. For example, the cleavage of the second cleavage agent can be non-chemical in nature. Therefore, in various embodiments, the second cleavage agent utilizes physical or mechanical force to crack intact cells. For example, the second cleavage agent can include cracking particles or beads, and the cracking particles or beads can give mechanical force to crack non-host species and release nucleic acids contained therein. In some instances, the cleavage of the second cleavage agent can be chemical in nature. For example, the second cleavage agent can include protease (such as proteinase K) etc., to crack non-host species and release nucleic acids contained therein. It should be understood that, according to the identity and properties of the non-host species to be cracked, other suitable cleavage agents can also be used to release nucleic acids contained therein.
[0084] In various embodiments, the cracked particles or beads include inorganic particles (such as silica particles, etc.); inorganic metal oxide particles (such as alumina, titania, zirconia, ceria, etc.); or combinations thereof. The average particle size of the cracked particles or beads may fall within the following ranges: about 100 μm to about 1000 μm, about 150 μm to about 950 μm, about 200 μm to about 900 μm; about 250 μm to about 850 μm; about 300 μm to about 800 μm; about 350 μm to about 750 μm; about 400 μm to about 700 μm; about 450 μm to about 650 μm; about 500 μm to about 600 μm; or about 500 μm to about 550 μm. In various embodiments, the average particle size of the cracked particles is about 500 μm.
[0085] In various embodiments, the method for detecting non-host species in host samples further includes applying an amplification process to host samples to amplify nucleic acids released from non-host species. Amplification reactions known in the art can be used. Amplification reactions may include, but are not limited to, polymerase chain reaction (PCR), ligase chain reaction (LCR), loop-mediated isothermal amplification (LAMP), amplification based on nucleic acid sequences (NASBA), self-sustaining sequence replication (3SR), rolling circle amplification (RCA) or any other process that can generate one or more copies of a specific nucleic acid sequence from a nucleic acid template sequence. Reverse transcription for generating a complementary DNA strand (cDNA) from RNA can be performed before amplification.
[0086] In various embodiments, the method for detecting non-host species in a host sample further comprises detecting the presence and / or identity of non-host nucleic acids that may have been amplified. The presence and / or identity of non-host nucleic acids can be detected according to any of the many methods available to those skilled in the art. In various embodiments, detection can be performed by performing assays including but not limited to DNA sequencing methods, next generation sequencing (NGS) methods, whole genome sequencing (WGS) methods, whole exome sequencing (WES) methods, gene panel sequencing methods, double-end sequencing methods, DNA microarray methods, etc. In the detection step, reverse transcription for generating a complementary DNA strand (cDNA) from RNA can be performed.
[0087] The method can also be used to detect infection in a subject. Therefore, in various embodiments, a method for detecting infection in a subject is provided, the method comprising: contacting a sample from the subject with a magnetic particle coupled to a nuclease to degrade cell-free host nucleic acids present in the sample, the nucleic acids are optionally released by a lysing agent (such as a mild detergent), wherein the magnetic particle coupled to the nuclease is capable of degrading both DNA and RNA; applying a magnetic field to remove the magnetic particle coupled to the nuclease from the sample; and detecting the presence of non-host nucleic acids in the sample. In various embodiments, the presence of non-host nucleic acids detected in the sample indicates that the subject has an infection. In various embodiments, the infection is selected from the group consisting of bacterial infection, fungal infection, protozoan infection, parasitic infection, viral infection, and a combination thereof. In various embodiments, the method further includes administering an anti-infective drug (such as an antibacterial, antiviral, antifungal, and antiparasitic drug / drug) to the subject when the subject is indicated to have an infection. In various embodiments, the method includes a diagnostic method.
[0088] The method can also be used to determine / evaluate / monitor the infection progress of a subject. In various embodiments, a method for determining / evaluating / monitoring the infection progress of a subject is provided, the method comprising: a) contacting a first sample from a subject with a magnetic particle coupled to a nuclease to degrade the cell-free host nucleic acid present in the first sample, wherein the magnetic particle coupled to the nuclease is capable of degrading both DNA and RNA; b) applying a magnetic field to remove the magnetic particle coupled to the nuclease from the first sample; c) detecting the presence and / or amount of non-host nucleic acid in the first sample; d) repeating steps a) to c) for a second sample from a subject; and e) comparing the amount of non-host nucleic acid in the first sample and the second sample, wherein the first sample is obtained from the subject at an earlier time point (e.g., several days or weeks ago) than the second sample. In various embodiments, it is found that the second sample contains a smaller amount of non-host species than the first sample, which indicates an improvement in infection in the subject. In various embodiments, when it is found that the second sample contains substantially the same or a larger amount of non-host species than the first sample, this indicates that the infection in the subject has not improved or worsened. In various embodiments, the method includes a prognostic method. For example, if the second sample is found to contain a lower amount of non-host species than the first sample, this may indicate that the subject has a good prognosis.
[0089] Advantageously, embodiments of the method can reduce / eliminate background signals and / or increase / enhance the signal of a nucleic acid of interest. Thus, in various embodiments, embodiments of the method show improved / high sensitivity for detecting infection / presence of non-host species in a subject.
[0090] Degradation of cell-free nucleic acids (such as RNA and / or DNA) can be useful for single-cell sequencing preparations. For example, in single-cell transcriptomics or genomics analysis, any cell-free nucleic acids incorporated into the emulsion are also labeled by a unique cell-specific barcode, which is undesirable. Therefore, removing cell-free nucleic acids first or early in the single-cell analysis / sequencing method can advantageously eliminate / reduce contamination caused by any cell-free nucleic acids, thereby improving the accuracy of the single-cell analysis / sequencing results. Therefore, in various embodiments, a method for single-cell analysis or sequencing is provided, the method comprising: contacting a sample containing a single cell with a magnetic particle coupled to a nuclease to degrade the cell-free nucleic acids present in the sample, wherein the magnetic particle coupled to the nuclease is capable of degrading both DNA and RNA; applying a magnetic field to remove the magnetic particle coupled to the nuclease from the sample; and sequencing nucleic acids from single cells. In various embodiments, the method further comprises a step of amplifying nucleic acids released from single cells before the sequencing step. Therefore, in various embodiments, sequencing nucleic acids from single cells comprises sequencing amplicons of nucleic acids from single cells. In various embodiments, amplifying nucleic acids released from single cells comprises amplifying nucleic acids with primers comprising barcode sequences to obtain amplified nucleic acids comprising barcode sequences. When sequencing multiple single cells, the barcode sequences can allow identification of the single cells from which the amplified nucleic acids are derived. For example, primers each comprising a unique cell-specific barcode sequence can be used to amplify nucleic acids derived from different single cells, thereby enabling the source of the amplified nucleic acids to be tracked based on the unique cell-specific barcode sequences marked thereon.
[0091] In various embodiments, the method comprises an in vivo, ex vivo, or in vitro method.
[0092] Also provided is a magnetic particle in the embodiment of the method disclosed herein. In various embodiments, the magnetic particle comprises one or more nucleases coupled thereto. The magnetic particle and the nuclease coupled thereto can include one or more properties previously described. In some embodiments, the magnetic particle is configured to provide DNAse and RNAse activity.
[0093] In various embodiments, a composition comprising a plurality of magnetic particles coupled to a nuclease is provided, wherein the plurality of magnetic particles can degrade RNA, DNA, or both RNA and DNA. In various embodiments, the plurality of magnetic particles include magnetic particles coupled to both DNAse and RNAse, magnetic particles coupled to nucleases that can degrade both DNA and RNA, mixtures of magnetic particles coupled to DNAse and magnetic particles coupled to RNAse, or combinations thereof. Magnetic particles and / or nucleases may include one or more properties described previously. In various embodiments, the composition includes a plurality of magnetic particles coupled to nucleases in a buffer solution. In various embodiments, the buffer solution has a pH that is substantially neutral or slightly alkaline. In various embodiments, the buffer solution has a pH of about 5 to about 9, about 6 to about 8, or from about 7 to about 8. In one embodiment, the pH of the buffer solution is about 7.5. The buffer solution may include salts, such as Tris-HCl, calcium chloride, sodium chloride, magnesium chloride, and other suitable salts.
[0094] In various embodiments, a kit is provided comprising a composition, a first cleaving agent, and / or a second cleaving agent. The first cleaving agent and the second cleaving agent may include one or more of the properties previously described.
[0095] In various embodiments, products or methods described herein are provided.
[0096] One-pot synthesis of DNA and RNA libraries
[0097] The following description relates to certain preferred embodiments for performing one-pot synthesis of DNA and RNA libraries. However, it will be appreciated that other one-pot synthesis techniques for creating DNA and RNA libraries can be used in the pathogen detection technology of the present invention.
[0098] In the following description, as a preferred example, a simultaneous amplification method for unbiased generation of a library from a mixture of different nucleic acids is shown. It will be apparent to those skilled in the art that modifications, including additions and / or substitutions, can be made without departing from the scope and spirit of the present invention. In order not to make the present invention unclear, specific details may be omitted; however, this disclosure is written to enable those skilled in the art to practice the teachings herein without excessive experimentation.
[0099] An unbiased simultaneous amplification method for preparing a library from a sample having more than one type of nucleic acid in substantially low amounts compared to non-nucleic acid molecules, the method comprising: providing a sample of more than one type of nucleic acid, including single-stranded and / or double-stranded DNA and / or RNA, as a template for subsequent extension and amplification; Preparing a first DNA strand from the sample, the preparing the first DNA strand comprising annealing one or more first DNA strand generating primers to any one of a DNA and / or RNA template, and extending from the annealed first DNA strand generating primers, the extending comprising using a DNA polymerase capable of synthesizing a first DNA strand from one or both of a DNA and / or RNA template in a one-pot method to obtain a first DNA strand, wherein the first DNA strand generating primers each comprise: A first nucleotide sequence comprising a constant linker sequence at the 5' end, followed by a polythymidine sequence and two random nucleotides, wherein the polythymidine sequence comprises at least ten thymidine bases, followed by a random nucleotide selected from the group consisting of adenine, cytosine or guanine, and further followed by a random nucleotide selected from the group consisting of four bases selected from adenine, cytosine, guanine and thymine; and a second nucleotide sequence comprising a constant linker sequence at the 5' end, followed by 5, 6 or 7 random nucleotides, wherein the random nucleotides are nucleotide bases randomly selected from the group consisting of any three bases of adenine, cytosine, guanine and thymine or a combination thereof; Preparing a second DNA strand or DNA fragment, the preparation of the second DNA strand comprises annealing a second DNA strand generating primer to the first DNA strand after the first DNA strand is dissociated from the DNA and / or RNA template and denatured, and extending from the annealed second DNA strand generating primer, the extension comprising using a DNA polymerase having strand displacement activity, wherein the second DNA strand generating primer comprises: a random nucleotide sequence at the 3' end of the second strand of DNA, the random nucleotide sequence comprising a plurality of the random nucleotides, and a second linker sequence at its 5' end, said sequence being physically linked to the random nucleotide sequence, The plurality of random nucleotides include at least five random nucleotides, wherein each of the at least five random nucleotides is selected from a set of any three bases of adenine, cytosine, guanine and thymine; Amplifying the second strand DNA or DNA fragment by polymerase chain reaction, wherein the amplification of the second strand DNA or DNA fragment comprises annealing a pair of amplification primers (the amplification primers comprising a first adapter sequence at the 5' end of one of the amplification primers and a second adapter sequence at the 5' end of the other amplification primer) with the second strand DNA or DNA fragment to obtain a plurality of amplicons, so that each amplicon comprises at least a first and a second adapter sequence; wherein each of the first and second adapter sequences has at least one methylated nucleotide; The amplicon is fragmented into a plurality of double-stranded DNA fragments, the fragmentation comprising reacting the amplicon with a methylation-specific restriction enzyme to obtain double-stranded DNA fragments lacking the first and second adapter sequences.
[0100] The random nucleotides may be selected from the group consisting of cytosine, guanine and thymine, the group consisting of adenine, guanine and thymine, the group consisting of adenine, cytosine and thymine or the group consisting of adenine, guanine, cytosine and thymine.
[0101] In another specific embodiment, each random nucleotide in the first strand generating primer is collectively or independently selected from B, D, H or V according to the IUPAC nucleotide code.
[0102] In yet another specific embodiment, each random nucleotide in the second strand generating primer is collectively or independently selected from B, D, H or V according to the IUPAC nucleotide code.
[0103] In a more specific embodiment, the random nucleotide sequence of the first strand generating primer and / or the second strand generating primer comprises 6 to 8 random nucleotides, wherein the last random nucleotide may be different from the remaining random nucleotides in the random nucleotide sequence according to the IUPAC nucleotide code.
[0104] In another more specific embodiment, the random nucleotide sequence of the first strand generating primer and / or the second strand generating primer comprises 6 to 8 random nucleotides, wherein, according to the IUPAC nucleotide code, except for the last random nucleotide, the remaining random nucleotides in the random nucleotide sequence are collectively selected from one of the random nucleotides, and the random nucleotide randomly selects three of the four nucleotide bases.
[0105] In another embodiment, methylated nucleoside triphosphates are added to the first and / or second DNA strand or DNA fragment preparation and / or to the reaction mixture of the polymerase chain reaction.
[0106] In a preferred embodiment, the methylated nucleoside triphosphate is deoxymethylcytidine triphosphate at a concentration of 0.01% to 25%, so that 0.01% to 25% of the cytosine in the product is methylated after the polymerase chain reaction.
[0107] In other embodiments, in the amplification primer, one cytosine in each of the first and second adapter sequences is modified by methylation to become methylcytosine, so as to obtain a plurality of amplicons having methylated nucleotide bases.
[0108] In another embodiment, the method further includes appending at least one pair of double-stranded adapters, wherein one chain thereof comprises single-stranded overhangs of 4 random nucleotides complementary to the single-stranded overhangs of 4 nucleotides at both ends of the fragmented double-stranded DNA fragments, so as to obtain double-stranded DNA fragments having a size of less than 1000 nucleotides containing double-stranded adapters appended at both ends thereof.
[0109] In another embodiment, the double-stranded DNA fragments to which the corresponding double-stranded adapters have been appended may further have a pair of sequencing adapters appended to both ends thereof for optional subsequent barcoding.
[0110] In another embodiment, if subsequent barcoding is intended, the double-stranded DNA fragments to which the corresponding double-stranded adapters have been appended are amplified by annealing a pair of primers prior to appending a pair of sequencing adapters to generate more amplicons.
[0111] A second aspect of the present invention relates to a kit for generating a library according to the methods described herein. The kit comprises a substrate conjugated with two of the first strand generating primers for annealing RNA templates (including single-stranded RNA templates and single-stranded mRNA). The kit also comprises a reaction mixture, a reverse transcriptase and RNAse for initiating reverse transcription of the first DNA strand from the annealed first strand generating primer. The kit also comprises a reaction mixture, a second strand generating primer and a polymerase with strand displacement activity for polymerizing the second DNA strand from the first DNA strand after separating the substrate from the liquid after reverse transcription. The kit also comprises a reaction mixture, an amplification primer and an enzyme for amplifying the second DNA strand, wherein the amplification primers correspond to the first strand generating primer and the second strand generating primer, respectively, in the linker sequences. The amplification product after the second DNA strand PCR amplification can be collected from the liquid phase of the reaction product.
[0112] The following are some advantages of using this method to generate library preparations for sequencing: (1) In the first strand generation, a melting scheme is used to generate the first strand from the total nucleic acid, allowing the random sequence to bind to both DNA and RNA molecules. A specific reverse transcriptase and adapter sequence are used in the first strand generation primer to generate the first DNA strand, allowing one-pot synthesis of the first strand DNA template from a mixture of different nucleic acids to avoid bias; (2) In the second strand generation, the second strand generation primer contains a random sequence to avoid the formation of concatemers when generating the second strand from the first DNA strand. Since the first DNA strand contains a linker sequence, the complementary linker sequence in the second strand generation primer produces a product with a unique identifier at either end of the second DNA strand; (3) inclusion of methylated dCT in the amplification primers (containing both adapter sequences for the first and second strand-generating primers) and addition of deoxymethylated cytosine triphosphates to the PCR reaction mixture allow subsequent restriction enzyme digestion with specificity for these amplicons at the methylated bases, thereby reducing the size of the fragments to less than 1000 nucleotides; (4) Appending adapter sequences with 4 nt 5' single-stranded overhangs allows for subsequent ligation of adapters at both ends of the DNA fragments for subsequent sequencing PCR and barcoding. Example
[0113] Through the following discussion and in conjunction with the accompanying drawings (if applicable), the exemplary embodiments of the present disclosure will be better understood and become apparent to those of ordinary skill in the art. It should be understood that other modifications related to structural, chemical and biological changes can be made without departing from the scope of the present invention. The exemplary embodiments are not necessarily mutually exclusive, because some embodiments can be combined with one or more embodiments to form new exemplary embodiments. The exemplary embodiments should not be interpreted as limiting the scope of the present disclosure.
[0114] Example 1 - Methods for removing unwanted nucleic acids from a sample according to exemplary embodiments disclosed herein Overview
[0115] refer to Figure 1 , a schematic flow chart showing various processing steps according to an exemplary embodiment of the method disclosed herein is shown. In this example, it is desirable to detect the presence and / or identity of non-host species (e.g., bacteria and viruses) residing in a host sample. Therefore, in this example, it is desirable to remove or degrade undesirable nucleic acids, i.e., extracellular host nucleic acids in a host sample, before detecting and identifying nucleic acids of non-host species.
[0116] In step 100, a sample obtained from a host is provided. The sample contains free host complexes 102 (e.g., lipoprotein complexes, extracellular vesicles, exosomes, organelles, or apoptotic bodies, etc.), bacteria 104, and viruses 106. Host complexes 102, bacteria 104, and viruses 106 contain nucleic acids in the form of DNA and RNA. Double-stranded DNA is represented by parallel straight lines, while single-stranded RNA is represented by wavy lines.
[0117] In step 200, magnetic beads 108 conjugated with nucleases (i.e., both DNAase and RNAse in this example) are incubated with a host sample in the presence of a lysing agent, which is in the form of a weak detergent. The weak detergent selectively cleaves the free host complex 102. The cracked host complex 110 releases the host RNA and DNA contained therein, which are then digested or degraded by the magnetic beads 108 conjugated with DNAase and RNAse. The degraded host DNA 114 and RNA 112 do not substantially affect the detection of non-host nucleic acids in subsequent steps. The weak detergent is substantially unable to degrade / digest bacteria 104 and viruses 106 to release the non-host nucleic acids contained therein.
[0118] In step 300, magnetic beads 108 conjugated with DNAse and RNAse are removed from a host sample using a magnet that provides magnetic force.
[0119] In step 400, another lysing agent is added to the sample, the lysing agent is in the form of lysing beads and / or proteinase K. The buffer solution already present in the sample in the previous step is not changed. The lysing agent is used to lyse non-host species (such as bacteria 104 and viruses 106) to produce lysed bacteria 116 and lysed viruses 118. Then, the lysed bacteria 116 and lysed viruses 118 allow the non-host nucleic acids (120, 122 and 124) contained therein to be released and leak into the sample for further processing and identification.
[0120] Example 2 - Illustrative embodiments of embodiments of the methods disclosed herein
[0121] In order to improve the detection sensitivity of non-host cell nucleic acid (for example, including nucleic acid from both DNA and RNA viruses) in host samples, both non-host DNA and RNA should be collected to obtain maximum signal. Using weak detergents to selectively lyse host complexes, combined with DNAse and RNAse to degrade host nucleic acids, can cause the selective exclusion of host nucleic acids, but it is difficult to remove DNAse and RNAse from samples before non-host organisms are lysed by methods such as bead-beating, particularly because RNAse is a very tenacious enzyme. This example shows that by utilizing magnetic particles conjugated with nucleases (such as DNAse and RNAse), free host nucleases in samples can be effectively degraded, and nucleases can be easily removed from host samples.
[0122] The obtained amplification plot ( Figure 2) shows amplification curves of PCR products using primers specific to each organism or representative human gene. Since PCR presumably doubles the product in each cycle, the cycle number (x-axis) reflects the logarithmic abundance of each product, and amplification curves shifted to the left reflect higher signals than amplification curves shifted to the right. The vertical lines drawn through each figure are calculated Ct values, corresponding to the predicted cycle number for a fixed fluorescence intensity, and can be considered a reflection of the relative abundance of each species.
[0123] Comparison of Ct values for bacterial, fungal, and viral fractions clearly demonstrated that these signals were largely identical or enhanced by bead treatment, whereas host human fractions were largely excluded. This indicates that the method clearly preferentially degrades host background signals and enriches for the relative contributions of non-host bacterial and fungal signals.
[0124] Example 3 - Preparation of library from HEK293 cells:
[0125] 10 ng or 1 ng of DNAse I-treated RNA harvested from HEK293 cells was mixed with 500 nM of adapter A-B6 (5′-CAGACTACCATGACCTGAGTCBBBBBB-3′) (SEQ ID NO: 1) and adapter A-oligodT (5′-CAGACTACCATGACCTGAGTCTTTTTTTTTTTTTTTVN-3′) (SEQ ID NO: 2) or adapter A-oligodT alone in a 10 μL reverse transcription reaction mix, using PROMEGA MMLV reverse transcriptase according to the manufacturer's instructions at 40°C for 15 minutes, followed by denaturation at 70°C for 5 minutes. 5 μL was stored for qPCR. To another 5 μL of the RT reaction mixture, 1 μL of 10 μM linker B-B8 (5'-GTCAGAGTCGAATGCGTACTGBBBBBBBB-3') (SEQ ID NO: 3) was added and heated to 70° C. for 2 minutes, and then cooled to 4° C. in a thermal cycler. Then, 1.5 μL of isothermal buffer, 1.0 μL of 25 mM MgSO4, 2.0 μL of 2 mM dNTP, 3.5 μL of water and 1 μL of Bst3.0 were added, and incubated at 45° C. for 20 s in a thermal cycler, increasing 1° C. to 60° C. every 20 s, and maintained at 60° C. for 12 minutes. Add 2.25 μL of 10 μM methylated adapter A primer (5'-CAGACTACmCATGACCTGAGTC-3') (SEQ ID NO: 4) and methylated adapter B primer (5'GTCAGAGTmCGAATGCGTACTG-3') (SEQ ID NO: 5), 4.5 μL 2mM dNTP, 0.9 μL 1 μM dmCTP, 3.6 μL KOD buffer, 2.25 μL 25mM MgSO4, 0.45 μL KOD, and add water to 45 μL. Then heat the template to 95°C for 2 minutes, and then cycle between 95°C for 10s, 58°C for 10s, and 70°C for 2 minutes for 10 cycles. Then clean the resulting 50 μL reaction mixture with 1.0× Ampure XP beads according to the manufacturer's instructions and elute in 10 μL ( Figure 8 ).
[0126] Example 4 - qPCR normalized to input RNA:
[0127] 5 μL RT is equivalent to 5 ng / 500 pg of HEK293 RNA input, while 10 μL of library prep cleaned with Ampure XP is equivalent to the same input. The RT reaction mixture saved in Example 1 was diluted 1:20, and the library prep was diluted 1:10, with 1 μL used for each qPCR. Then, a PCR product targeting human 18S ( Fig. 7A)、U2AF1( Figure 7B )、GAPDH coding region ( Figure 7C ) and GAPDH3′UTR( Fig.7D ) were used to perform qPCR. After amplification according to the methods described herein, it was confirmed that all amplicons were amplified using the unbiased amplification method described herein.
[0128] Example 5-DNA fragmentation and library preparation:
[0129] Then 3 μL of the Ampure XP purified library from Example 1 was digested with MspJI in a 5 μL reaction at 37° C. for 15 minutes according to the manufacturer's instructions to fragment the library. Then 1.5 μL of double-stranded adapters, one of which is represented by (5′-AGATGTGTATAAGAGACAG-3′) (SEQ ID NO: 6) and the other by (5′-NNNNCTGTCTCTTATACACATCT-3′) (SEQ ID NO: 7), 7 μL of 2× Quick Ligase buffer (NEB), 0.5 μL of 2 mM dNTPs, 0.3 μL of Recombinant Taq, and 0.7 μL of Quick Ligase were added to ligate adapters to the ends. It was then amplified with two primers (5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3′) (SEQ ID NO: 8) and (5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3′) (SEQ ID NO: 9) in a KOD reaction with an annealing temperature of 60° C. and an extension of 40 seconds for 10 cycles. The reaction was then barcoded using ILLUMINA barcoding primers and sequenced on the iSeq 100 according to the manufacturer's protocol.
[0130] The following provides examples of thermal cycler settings and conditions (in Tables 3-10) for generating libraries from reagents according to Tables 1 and 2: 1) Add up to 3 μL of nucleic acid sample to 1 μL of the reaction mixture of primers, water and nucleotides shown in SEQ ID NO: 1-SEQ ID NO: 2, and if necessary, add nuclease-free water to 4 μL. Place in a thermal cycler with the following settings (Table 1). Table 1: 2) Add 1 μL of reverse transcriptase (from NEB) and place in a thermal cycler with the following settings (Table 2). Table 2: 3) Add 4 μL of the primer shown in SEQ ID NO: 3, a reaction mixture containing an isothermal buffer, oligonucleotides and water, and 1 μL of a polymerase with strand displacement activity on ice to a total volume of 10 μL, and place in a thermal cycler with the following settings (Table 3). Table 3 4) Add 15 μL of reagents from the KOD kit and a pair of amplification primers represented by SEQ ID NO: 4 and SEQ ID NO: 5, respectively, wherein the 9th cytosine from the 5' end of each amplification primer is methylated, and place in a thermal cycler with the following settings (Table 4). Table 4: 5) Add 25 μL of Ampure XP (diluted) beads that have been warmed to room temperature and mix by pipetting up and down at least 10 times and allow the sample and beads to incubate at room temperature for at least 3 minutes. 6) Pull the beads out using a magnetic rack. Leave on the rack for at least 2 minutes. 7) Remove the supernatant and resuspend the beads in 100 μL of freshly prepared 80% ethanol. Place on a magnetic stand for 20 seconds to pull the beads out. Repeat this step once more. 8) Remove the supernatant, allow the beads to dry at room temperature for 5 minutes, and then resuspend them thoroughly in 8 μL of nuclease-free water. Incubate at room temperature for 1 minute and place on a magnetic stand. 9) Carefully remove the eluate and transfer to a new tube. 10) Take 4 μL of the eluate and add 1 μL of the reagent from the MspJI kit to a new tube and place in a thermal cycler with the following settings (Table 5). Table 5: 11) Add 10 μL of reagents from the Quick Ligase and Taq kits and primers shown as SEQ ID NO: 6 and SEQ ID NO: 7, respectively, to the sample to give a total volume of 15 μL and place in a thermal cycler with the following settings (Table 6). Table 6: 12) Add 25 μL of reagents from the KOD kit and primers shown as SEQ ID NO: 8-SEQ ID NO: 9, respectively, to the sample to give a total volume of 40 μL, and place in a thermal cycler with the following settings (Table 7). Table 7: 13) Take 5 μL of the sample from step 12, add 0.8 μL of each barcoded primer, and 13.4 μL of the same reagents from the KOD kit as in step 12 to give a total of 20 μL, and place in a thermal cycler with the following settings (Table 8). Table 8: 14) Add 20 μL of Ampure XP (diluted) beads that have been warmed to room temperature, mix by pipetting up and down at least 10 times and allow the sample and beads to incubate at room temperature for at least 3 minutes. 15) Pull the beads out using a magnetic rack. Leave on the rack for at least 2 minutes. 16) Remove the supernatant and resuspend the beads in 100 μL of freshly prepared 80% ethanol. Place on a magnetic stand for 20 seconds to pull the beads out. Repeat this step once more. 17) Remove the supernatant and allow the beads to dry at room temperature for 5 minutes, then resuspend them thoroughly with 8 μL of nuclease-free water. Incubate at room temperature for 1 minute and place on a magnetic stand. 18) Carefully remove the eluate and transfer to a fresh tube. 19) The library is ready for sequencing. NB: If the cells in the column showing the number of cycles are empty, this indicates 1 cycle.
[0131] like Figure 8 The sequencing results shown in Table 9 indicate that the library prepared according to the present method can detect more than 9,000 genes expressed in HEK cells, with a read depth between 60,000 and 90,000 reads. Table 9: dT_B6_5ng dT_5ng Total Read Segments 63858 84849 Number of mapped transcripts 9410 12266
[0132] In addition, the read distributions of dT_5ng and dT_B6_5ng were very similar, except for transcripts without polyA tails (such as 7SK, mt-RNR1, and mt-RNR2). These results indicate that the proposed method generates unbiased and representative libraries.
[0133] Example 6-Comparison of N, B, D, H and NTC in terms of background amplification
[0134] To identify potential background amplification, 0.4 μL of 5 μM N6 (CAGACTACCATGACCTGAGTCNNNNNN) (SEQ ID NO: 10), B6 (CAGACTACCATGACCTGAGTCBBBBBB) (SEQ ID NO: 1), D6 (CAGACTACCATGACCTGAGTCDDDDDD) (SEQ ID NO: 11), or H6 (CAGACTACCATGACCTGAGTCHHHHHH) (SEQ ID NO: 12) was mixed with 0.2 μL 25 mM dNTPs, 1.0 μL 5× PROMEGA MMLV reverse transcriptase buffer, and 3.1 μL water, heated to 70° C. for 30 seconds, and cooled to 4° C. Then, 0.5 μL PROMEGA MMLV reverse transcriptase was added, and the reaction was incubated at 40° C. for 15 minutes, and then at 70° C. for 5 minutes.
[0135] As described above, 1.5 μL NEB isothermal buffer, 0.75 μL 25 mM MgSO4, 1.5 μL 2 mM dNTPs, 0.5 μL Bst3.0, 4.8 μL water, and 1.0 μL N8 (GTCAGAGTCGAATGCGTACTGNNNNNNNN) (SEQ ID NO: 13), B8 (GTCAGAGTCGAATGCGTACTGBBBBBBBB) (SEQ ID NO: 3), D8 (GTCAGAGTCGAATGCGTACTGDDDDDDDD) (SEQ ID NO: 14), or H6 (GTCAGAGTCGAATGCGTACTGHHHHHHHH) (SEQ ID NO: 15) were added to the corresponding sample tubes.
[0136] The samples were incubated at 45° C. for 20 s and the temperature was increased in steps of 1° C. every 20 s until the samples reached 60° C. The samples were further incubated at 60° C. for 10 min.
[0137] The resulting sample was diluted 1 / 100 and 1 μL was placed in a 20 μL qPCR reaction using Solis Biodyne's FIREPOL SyBr Green qPCR mastermix and the following primers (GTCAGAGTCGAATGCGTACTG) (SEQ ID NO: 17) and (CAGACTACCATGACCTGAGTC) (SEQ ID NO: 18) according to the manufacturer's instructions and cycled with the following protocol: 95°C for 15s, 60°C for 15s, 72°C for 40s, for 50 cycles.
[0138] The resulting qPCR Ct (Table 10) reveals the background levels for the "empty" reactions using different pools of random hexamers and octamers. For N, the low Ct indicates that the background signal is significantly higher than the bases of the B, D or H pools.
[0139] Therefore, repeating random hexamers or octamers of B, D or H at the 3' end of the adapter sequences of the first and second DNA strand-forming primers reduces the chance of non-specific priming compared to repeating N at the same region of the strand-forming primers. Table 10: sample N6+N8 B6+B8 D6+D8 H6+H8 NTC Copy 1 14.9 15.44 18.76 20.91 31.33 Copy 2 14.89 15.38 17.93 20.92 26.15
[0140] Example 7
[0141] The following examples illustrate how to prepare a DNA library according to other embodiments of the present invention: 1. Prepare 5 pM B5V1:dT by mixing 9.5 μL 100 pM B5V1 (shown in SEQ ID NO: 1) and 0.5 μL dT (shown in SEQ ID NO: 2) with 190 μL water; 2. 100 μM B7V1 (shown as SEQ ID NO: 3) purchased from the oligonucleotide manufacturer was used as received; 3. Mix 3 μL of 100 μM mC F (shown in SEQ ID NO: 4, wherein the cytosine at the 9th nucleotide from the 5′ end is methylated), 3 μL of 100 μM mC R (shown in SEQ ID NO: 5, wherein the cytosine at the 9th nucleotide from the 5′ end is methylated), 1 μL of 10 mM dmCTP (NEB), and 23 μL of water; 4. Mix 3 μL of 100 μM adapter F (shown in SEQ ID NO: 6), 3 μL of 100 μM adapter R (shown in SEQ ID NO: 7), 3 μL of 1 M sodium chloride, 3 μL of 10×TE buffer, and 18 μL of water. Heat to 95°C, and cool to 4°C at 0.25°C per second to prepare a 10 μM adapter mixture; 5. Mix 15 μL of 100 μM i5 F (shown in SEQ ID NO: 8) and 15 μL of 100 μM i7 R (shown in SEQ ID NO: 9) to prepare 50 μM i5 i7 Amp.
[0142] In separate boxes prepare 15 μL tubes with different primers for barcoding.
[0143] Example 8 - Functional Quality Control (QC) of DNA Library Preparation:
[0144] 5 ng HEK293 in 3 μL was processed with the AmpRE kit and run on a gel or TapeStation. A smear of 200nt-500nt should be seen.
[0145] Those skilled in the art will appreciate that other changes and / or modifications may be made to the embodiments disclosed herein without departing from the spirit or scope of the disclosure as broadly described. For example, in the description herein, features of different exemplary embodiments may be mixed, combined, interchanged, merged, adopted, modified, or included, etc. across different exemplary embodiments. Therefore, the present embodiments are to be considered in all respects as illustrative and not restrictive.
[0146] Unless otherwise defined, all technical terms, symbols and other scientific terms or technical terms used herein are intended to have the meanings commonly understood by those skilled in the art to which the present invention belongs. In some cases, terms with commonly understood meanings are defined herein for clarity and / or ease of reference, and the inclusion of such definitions herein should not necessarily be interpreted as indicating substantial differences compared to those commonly understood in the art. It should be further understood that terms (such as those defined in commonly used dictionaries) should be interpreted as having meanings consistent with their meanings in the relevant art and / or otherwise defined herein.
Claims
1. A metagenomic sequencing process for a body fluid sample, wherein the improvements in the process include: degrading unwanted nucleic acids in the sample by contacting the sample with magnetic particles coupled to an enzyme for degrading unwanted nucleic acids present in the sample, wherein the magnetic particles coupled to the enzyme are capable of degrading both DNA and RNA, and subsequently applying a magnetic field to remove the magnetic particles coupled to the enzyme from the sample; and Create DNA and RNA libraries from degraded samples in a one-pot process.
2. The metagenomic sequencing process according to claim 1, wherein: The enzyme is a nuclease.
3. The metagenomic sequencing process according to claim 1, wherein: The one-pot process uses one set of primers to prime single-stranded DNA and simultaneously prime RNA.
4. The metagenomic sequencing process according to claim 1, wherein: The sample contains more than one type of nucleic acid as a template for subsequent extension and amplification, the nucleic acid including single-stranded and / or double-stranded DNA and / or RNA, And the one-pot process includes preparing a first DNA chain from the sample, wherein the preparing the first DNA chain includes annealing one or more first DNA chain generating primers to any one of the DNA and / or RNA templates; and extending from the annealed first DNA chain generating primers, wherein the extending includes using a DNA polymerase capable of synthesizing a first DNA chain from one or both of the DNA and / or RNA templates to obtain the first DNA chain.
5. The metagenomic sequencing process according to claim 1, wherein: The enzyme-coupled magnetic particles include magnetic particles coupled to both DNAse and RNAse, magnetic particles coupled to enzymes capable of degrading both DNA and RNA, a mixture of magnetic particles coupled to DNAse and magnetic particles coupled to RNAse, or a combination thereof.
6. The metagenomic sequencing process according to claim 1 or 2, wherein: The undesired nucleic acids include cell-free nucleic acids.
7. The metagenomic sequencing process according to any one of claims 1 to 5, wherein: Degrading unwanted nucleic acids in the sample further comprises applying a lysing agent to the sample for selectively lysing biological complexes in the sample to release the unwanted nucleic acids for degradation by the enzyme, optionally wherein the lysing agent is substantially incapable of lysing intact cells and viruses selected from bacteria, protozoa, fungi and parasites.
8. The metagenomic sequencing process according to claim 6, wherein: The lysing agent includes a mild detergent.
9. The metagenomic sequencing process according to any one of claims 1 to 7, wherein: The sample comprises a sample derived from a host subject and the undesired nucleic acids comprise host nucleic acids but are substantially free of non-host nucleic acids.
10. The metagenomic sequencing process according to claim 9, wherein: The enzyme is a nuclease.
11. A method for detecting a non-host species in a host sample, the method comprising: contacting the host sample with magnetic particles coupled to an enzyme to degrade cell-free host nucleic acids present in the host sample, wherein the magnetic particles coupled to the enzyme are capable of degrading both DNA and RNA; applying a magnetic field to remove the enzyme-coupled magnetic particles from the host sample; One-pot process to create DNA and RNA libraries from degraded samples; and The DNA and RNA libraries are detected for the presence of non-host nucleic acids.
12. The method of claim 11, wherein: The one-pot process uses one set of primers to prime single-stranded DNA and simultaneously prime RNA.
13. The method of claim 11, wherein: The sample contains more than one type of nucleic acid as a template for subsequent extension and amplification, the nucleic acid including single-stranded and / or double-stranded DNA and / or RNA, And the one-pot process includes preparing a first DNA chain from the sample, wherein the preparing the first DNA chain includes annealing one or more first DNA chain generating primers to any one of a DNA and / or RNA template; and extending from the annealed first DNA chain generating primers, wherein the extending includes using a DNA polymerase capable of synthesizing a first DNA chain from one or both of a DNA and / or RNA template to obtain the first DNA chain.
14. The method of claim 11, further comprising removing host cells from the host sample before contacting the host sample with the enzyme-coupled magnetic particles.
15. The method of claim 11, further comprising applying a first cleavage agent to the host sample prior to the contacting step for selectively cleaving the biological complex to release the host nucleic acid contained therein, optionally wherein the first cleavage agent is substantially incapable of cleaving non-host species to release the nucleic acid contained therein for degradation by the enzyme.
16. The method of claim 15, wherein: The lysing agent includes a mild detergent.
17. The method of claim 11, wherein: The step of detecting the presence of non-host nucleic acid in the sample comprises: A second lysing agent is applied to the host sample to lyse the non-host species to release the nucleic acids contained therein.
18. The method of claim 11, wherein: The second lysing agent comprises lysing particles capable of imparting mechanical forces to lyse the non-host species and release the nucleic acids contained therein.
19. The method of claim 11, wherein: Detecting the presence of the non-host nucleic acid in the sample comprises sequencing the non-host nucleic acid.
